Condition Focus: Bone Cell Biology — Cell-Type Specific Dose Response
One of the most important insights for PBM device design is that different cell types respond optimally to different energy densities. This study from Na and colleagues in the Journal of Biomedical Optics systematically tested PBM at 1, 5, and 7.5 J/cm² on three bone cell types — osteoblasts, osteoclasts, and osteocytes — and found distinct dose-response profiles for each.
Osteoblasts (bone builders) showed enhanced proliferation at 1 J/cm² — the lowest dose. Osteoclasts (bone destroyers) showed decreased viability at 5 J/cm² — a higher dose. Osteocytes (bone maintenance cells embedded in mineralised matrix) responded differently again. This creates a therapeutic window where specific doses can simultaneously promote bone formation while reducing bone resorption — the ideal outcome for conditions like gout where inflammatory bone erosion is a concern.
The hormetic pattern is consistent with the Arndt-Schulz curve that characterises PBM: low doses stimulate, optimal doses produce peak effects, and excessive doses provide diminishing or inhibitory returns. But this study adds the critical nuance that “optimal” is not one number — it varies by cell type within the same tissue.
For device design, this means the energy density reaching different cell populations within the target tissue matters. In a joint, osteoblasts are at the bone surface, osteoclasts are in resorption lacunae, and chondrocytes are in the cartilage layer — each potentially receiving a different effective dose due to depth-dependent light attenuation. This depth-dependent dose gradient may actually be advantageous, naturally delivering different doses to different cell types.
G.O.A.T. for Gout Alignment:
The G.O.A.T.’s 4 J/cm² target falls between the osteoblast-stimulating (1 J/cm²) and osteoclast-suppressing (5 J/cm²) optima identified here. With depth-dependent attenuation through overlying tissue, the effective dose reaching bone cells may naturally approximate the optimal range for each cell type.
Link to original research here
Editor’s note: The cell-type specific dosing identified here is applied in the co-culture bone remodeling system by Hong et al 2022. The comprehensive bone repair parameter review is provided by Lu et al 2024. The Arndt-Schulz biphasic curve underlying these dose responses is explained in Huang et al 2009. For the broader connective tissue dose-dependence pattern, see Houreld et al 2022.
Related Articles
- PBM Effects on Bone Remodeling in Osteoblast-Osteoclast Co-Culture – Hong et al 2022
- The Role of PBM in Accelerating Bone Repair – Lu et al 2024
- Biphasic Dose Response in PBM: Arndt-Schulz Curve – Huang et al 2009
- PBM, Cells of Connective Tissue and Repair – Houreld et al 2022
- PBM in Proliferation/Differentiation of Stem Cells – Miranda et al 2020
Key Takeaways
- Each bone cell type has a different optimal PBM dose: osteoblasts at 1 J/cm², osteoclasts at 5 J/cm²
- Depth-dependent dose attenuation in tissue may naturally deliver appropriate doses to each cell layer
- Hormetic pattern consistent with Arndt-Schulz curve but cell-type specific
- Therapeutic window exists where bone formation is enhanced AND bone resorption is suppressed
Study Overview
| Study Type: | In vitro (dose-response) |
| Wavelength(s): | Not specified in abstract |
| Treatment Protocol: | 1, 5, 7.5 J/cm² on three bone cell types |
| Sample Size: | Osteoblast, osteoclast, and osteocyte cultures |
| Primary Outcome: | Cell-type specific dose response: osteoblast↑ at 1 J/cm², osteoclast↓ at 5 J/cm² |
Full Citation
Na S, et al. (2018). Dose analysis of photobiomodulation therapy on osteoblast, osteoclast, and osteocyte. Journal of Biomedical Optics, 23(7), 075008. View Publication
